CONMED Corporation Announces Quarterly Cash Dividend

UTICA, N.Y.–(BUSINESS WIRE)–CONMED Corporation (NASDAQ: CNMD) today announced that its Board
of Directors has declared a quarterly cash dividend of $0.20 per share,
payable on July 5, 2019 to all shareholders of record as of June 14,
2019.

About CONMED Corporation

CONMED is a medical technology company that provides surgical devices
and equipment for minimally invasive procedures. The Company’s products
are used by surgeons and physicians in a variety of specialties,
including orthopedics, general surgery, gynecology, neurosurgery,
thoracic surgery and gastroenterology. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release may contain forward-looking statements based on
certain assumptions and contingencies that involve risks and
uncertainties, which could cause actual results, performance, or trends
to differ materially from those expressed in the forward-looking
statements herein or in previous disclosures. For example, in addition
to general industry and economic conditions, factors that could cause
actual results to differ materially from those in the forward-looking
statements may include, but are not limited to, the risk factors
discussed in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2018 and listed under the heading Forward-Looking
Statements
in the Company’s most recently filed Form 10-Q. Any and
all forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995 and
relate to the Company’s performance on a going-forward basis. The
Company believes that all forward-looking statements made by it have a
reasonable basis, but there can be no assurance that management’s
expectations, beliefs or projections as expressed in the forward-looking
statements will actually occur or prove to be correct.

Contacts

CONMED Corporation
Todd Garner
Chief
Financial Officer

315-624-3317
ToddGarner@conmed.com

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

17 minutes ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

17 minutes ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

17 minutes ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

17 minutes ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

18 minutes ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

18 minutes ago